Related Experiment Videos
[Systemic ALlambda amyloidosis associated with vascular fragility]
Martin Laimer1, Karin Kaindl, Michael Emberger
1Universitätsklinik für Dermatologie, Paracelsus Medizinische Privatuniversität Salzburg, Osterreich.
Summary
Systemic ALlambda amyloidosis caused periorbital hemorrhage and hemoptysis in a patient. Treatment with melphalan and prednisolone improved outcomes, highlighting advances in managing this condition.
Area of Science:
- Internal Medicine
- Hematology
- Pathology
Background:
- Systemic amyloidosis is a rare condition characterized by extracellular deposition of misfolded proteins.
- ALlambda amyloidosis, a subtype, involves immunoglobulin light chains and can affect multiple organs.
Observation:
- A 63-year-old patient presented with a year of bilateral periorbital hemorrhage and recurrent hemoptysis.
- Skin and colon biopsies confirmed systemic ALlambda amyloidosis, with suspected heart and lung involvement.
- Bone marrow examination ruled out monoclonal gammopathy.
Findings:
- A non-aggressive treatment regimen of monthly melphalan and prednisolone was initiated.
- The patient showed significant improvement in clinical parameters following treatment.
- This case underscores the importance of early diagnosis and tailored therapy.
Implications:
- Advances in diagnostic tools and therapeutic strategies are improving the management of systemic amyloidosis.
- Even in cases without monoclonal gammopathy, ALlambda amyloidosis can be effectively treated.
- This case highlights a successful therapeutic approach for a rare and often severe condition.